Asset Details
Do you wish to reserve the book?
Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
Do you wish to request the book?
Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
2003
Overview
Measurement of the transcripts of
BCR-ABL,
the key molecular abnormality in chronic myeloid leukemia (CML), provides an estimate of the burden of leukemic cells in a given patient. A profound reduction in blood levels of
BCR-ABL
transcripts was much more frequent among patients treated with imatinib than among those treated with interferon alfa plus cytarabine.
Responses superior to those with interferon plus cytarabine.
Chronic myeloid leukemia (CML) is a clonal disease of the hematopoietic stem cell in which a reciprocal translocation, t(9;22)(q34;q11), forms the Philadelphia chromosome (Ph) and creates a novel fusion gene,
BCR-ABL
.
1
This gene expresses an activated tyrosine kinase that is central to the pathogenesis of CML.
2
,
3
The median survival among patients with CML is three to six years, with most deaths resulting from progression of the disease into a blastic phase. Survival among patients treated with interferon alfa is superior to that among patients treated with hydroxyurea.
4
The addition of cytarabine to interferon alfa may further improve median . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Antineoplastic Agents - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biological and medical sciences
/ Cytarabine - therapeutic use
/ Female
/ Fusion Proteins, bcr-abl - blood
/ Hematologic and hematopoietic diseases
/ Humans
/ Interferon-alpha - therapeutic use
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
/ Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
/ Male
/ Piperazines - therapeutic use
/ Pyrimidines - therapeutic use
